CatalystMarker
← board

PRNAD

Alterity Therapeutics
$0.060%today-90% from 52w high
alteritytherapeutics.com9 employeesFounded 1997Melbourne, VIC
Lead: Multiple System Atrophy
Revenue
pre-revenue
Liquidity
—
Runway
—
Shares 1y
—

Price & events

-88.7% over 6M
$0.01$0.26$0.50Jan 26Apr 26Jul 2610k
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
+0.0%
1M
+0.0%
3M
-89.8%
6M
-63.3%
1Y
—
2Y
—
5Y
-69.4%
All

Overview

Market Cap
$502.01M
Volume
0
52 Week Range
$0.01 – $0.54
Total Shares
9.13B
Float Shares
172.83M
% Held by Insiders
8.27%
% Held by Institutions
17.88%
Beta
-0.03

Pipeline stages · 1 programs

ATH434
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved

Pipeline · 1 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
2025-02-26
Phase 2ATH434Multiple System Atrophy10completed

Catalyst news & presentations · 0

  • No catalyst news yet.

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 9,127,370,686
  • none
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors — Multiple System Atrophy

  • TEVATEVA PHARMACEUTICAL INDUSTRIES LTD$35.2B · D0
  • TBPHTheravance Biopharma, Inc.$869M · D0
  • TLSATiziana Life Sciences Ltd$114M · D6

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.